Rubio-Viqueira Belen, Tarruella Margarita Majem, Lázaro Martín, Estévez Sergio Vázquez, Córdoba-Ortega Juan Felipe, Maiques Inmaculada Maestu, González Jorge García, Cordellat Ana Blasco, Valdivia-Bautista Javier, Arenas Carmen González, Sánchez Torres Jose Miguel
Department of Medical Oncology, Quirónsalud Madrid Hospital, Pozuelo de Alarcón, Madrid, Spain.
Department of Medical Oncology, Santa Creu i Sant Pau Hospital, Barcelona, 08041, Spain.
Lung Cancer Manag. 2021 Nov 26;10(4):LMT53. doi: 10.2217/lmt-2021-0008. eCollection 2021 Dec.
To describe the clinical management and PD-L1 testing of patients with newly diagnosed stage IV non-small cell lung cancer (NSCLC) without driver mutations in Spain.
Multicenter, retrospective study.
Among 297 evaluated patients, 89.2% received systemic treatment for stage IV disease, of whom 53.6% received platinum doublet therapy, 26.8% immunotherapy as monotherapy and 14.7% immunotherapy + chemotherapy, with 9.4% receiving treatment as part of a clinical trial. Treatment was initiated 1 month after histological diagnosis, with PD-L1 test results available in most cases (92.6%). PD-L1 testing was performed in 287 patients, 95.1% by in-house tests, mostly with the 22C3 pharmDx assay. The factor most strongly associated with treatment selection was, as expected, the expression of PD-L1.
PD-L1 testing is implemented in clinical practice and seems to guide treatment decisions in patients with NSCLC in Spain.
描述西班牙新诊断的无驱动基因突变的IV期非小细胞肺癌（NSCLC）患者的临床管理及程序性死亡受体1配体（PD-L1）检测情况。
多中心回顾性研究。
在297例接受评估的患者中，89.2%的患者接受了IV期疾病的全身治疗，其中53.6%接受了铂类双联疗法，26.8%接受了免疫疗法单药治疗，14.7%接受了免疫疗法+化疗，9.4%作为临床试验的一部分接受治疗。治疗在组织学诊断后1个月开始，大多数情况下（92.6%）可获得PD-L1检测结果。287例患者进行了PD-L1检测，95.1%通过内部检测，主要采用22C3免疫组化检测法。正如预期的那样，与治疗选择最密切相关的因素是PD-L1的表达。
PD-L1检测在临床实践中得以实施，似乎可指导西班牙NSCLC患者的治疗决策。
